GlassScriptPhysician profile
Mark W Lefler
NPI 1255310819
$1,517.04
in general payments reported to CMS, 2019-2025
20 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $194 · 2021: $320 · 2022: $283 · 2023: $244 · 2024: $109 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.52 | 2021-2025 | |
| Pfizer INC. | $246.26 | 2019-2024 | |
| Amgen INC. | $167.95 | 2019-2025 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $145.52 | 2020-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $112.12 | 2021-2025 | Freestyle Libre 3, Cardiomems |
| Novartis Pharmaceuticals Corporation | $97.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $54.41 | 2019-2022 | |
| Dexcom, INC. | $45.53 | 2021-2022 | |
| Glaxosmithkline, LLC. | $44.93 | 2020-2022 | |
| Lilly USA, LLC | $43.22 | 2022-2025 | Kisunla |
| Jazz Pharmaceuticals INC. | $35.03 | 2021 | |
| Allergan, INC. | $29.80 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.06 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.41 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.19 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $15.69 | 2022 | |
| Esperion Therapeutics, INC. | $13.86 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.11 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lefler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.